Publication: Nueva herramienta terapéutica en el tratamiento de la leucemia mieloide crónica
Loading...
Official URL
Full text at PDC
Publication Date
2018-02
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
La Leucemia Mieloide Crónica (LMC) es una neoplasia mieloproliferativa crónica que afecta a las células precursoras de la sangre. Se origina por una mutación genética característica, la translocación entre los cromosomas 9 y 22, generando un oncogén BCR-ABL (cromosoma Ph). Es una enfermedad difícil de curar de forma definitiva. Actualmente sólo se logra mediante un trasplante alogénico de células madre, pero no es fácil realizarlo debido a la dificultad para encontrar un donante compatible. Por ello se usan, entre otros, los inhibidores de la tirosina cinasa (ITC) que consiguen frenar el progreso de la enfermedad. Recientemente se está investigando sobre una terapia de edición genética (CRISPR-Cas), que podría eliminar de forma definitiva el oncogén.
CML is a Chronic Myeloproliferative Neoplasm affecting the precursor cells of the blood. It arises from a genetic mutation, which consists of a translocation between conversations 9 and 22 that result in an oncogene BCR-ABL (Ph chromosome). It is a disease hard to cure permanently. Currently, the only definitive treatment is to transplant allogenic stem cells, but compatible donors are difficult to find. For this reason, tyrosine kinase inhibitors (TKI) are used, among others, to slow down the progression of the disease. Recently researches have focused on gene therapy through CRISPR-Cas, which attempts to knock out the oncogene.
CML is a Chronic Myeloproliferative Neoplasm affecting the precursor cells of the blood. It arises from a genetic mutation, which consists of a translocation between conversations 9 and 22 that result in an oncogene BCR-ABL (Ph chromosome). It is a disease hard to cure permanently. Currently, the only definitive treatment is to transplant allogenic stem cells, but compatible donors are difficult to find. For this reason, tyrosine kinase inhibitors (TKI) are used, among others, to slow down the progression of the disease. Recently researches have focused on gene therapy through CRISPR-Cas, which attempts to knock out the oncogene.